Infrarenal by Choice

GORE® EXCLUDER® AAA Endoprosthesis

- Most studied* EVAR device
- EVAR market leader
- > 350,000+ patients treated†
- Over 20 years of experience
- Low rates of:‡
  - Migration
  - Type IA endoleak
  - Reintervention
  - Limb occlusion
  - Renal complications

Proven performance. Proven outcomes.

The most-studied* EVAR device delivers durable outcomes for your patients.

3,274 Patients — Follow-up through 5 Years‡

0.9%	0.0%§	0.4%
Type IA endoleak	Migration	Renal complications‖

* Based on company-sponsored trials and registries shown on clinicaltrials.gov for currently available stent grafts.

† Based on the number of Trunk-Ipsilateral Legs distributed.

‡ GREAT. n = 3,274. To calculate the overall event rates from procedure through end of study period, all subjects who could have had events, regardless of length of follow-up, were included. For outcome data, GREAT only collects site reported serious adverse events. Therefore, all reported endoleaks are defined as serious and require reintervention.

§ One peri-procedural migration reported. Zero migrations reported during follow-up through 5 years.

‖ Inclusion for renal complication rate: Subjects with renal complication were identified with MedDRA code. Of those identified with MedDRA code as having a renal complication, only those who showed the SAE occurring within 75 days of the procedure AND were reported by the site/physician as being related to the device or procedure were included in the renal complication rate.

GORE

Creative Technologies Worldwide

The GORE® C3® Delivery System is repositionable to obtain optimal seal

- A unique delivery system provides the ability to reconstrain the proximal end of the device and reposition for ideal placement
- More opportunities to maximize infrarenal seal



Data from GREAT:* 400 Patients, 13 EU sites, August 2010–December 2012

48.1% Physicians used repositioning

79%
Optimized position to renal arteries

20%
Contralateral gate cannulation

* GREAT. n = 3,274. To calculate the overall event rates from procedure through end of study period, all subjects who could have had events, regardless of length of follow-up, were included. For outcome data, GREAT only collects site reported serious adverse events. Therefore, all reported endoleaks are defined as serious and require reintervention.

INDICATIONS FOR USE: Trunk-Ipsilateral Leg Endoprosthesis and Contralateral Leg Endoprosthesis Components. The GORE® EXCLUDER® AAA Endoprosthesis is intended to exclude the aneurysm from the blood circulation in patients diagnosed with infrarenal abdominal aortic aneurysm (AAA) disease and who have appropriate anatomy as described below: Adequate iliac / femoral access; Infrarenal aortic neck treatment diameter range of 19–32 mm and a minimum aortic neck length of 15 mm; Proximal aortic neck angulation ≤ 60°; Iliac artery treatment diameter range of 8–25 mm and iliac distal vessel seal zone length of at least 10 mm. **Aortic Extender Endoprosthesis and Iliac Extender Endoprosthesis Components.** The Aortic and Iliac Extender Endoprostheses are intended to be used after deployment of the GORE® EXCLUDER® AAA Endoprosthesis. These extensions are intended to be used when additional length and / or sealing for aneurysmal exclusion is desired. **CONTRAINDICATIONS:** The GORE® EXCLUDER® AAA Endoprosthesis is contraindicated in patients with known sensitivities or allergies to the device materials and patients with a systemic infection who may be at increased risk of endovascular graft infection. Refer to *Instructions for Use* at goremedical.com for a complete description of all warnings, precautions and adverse events. ℞ Only

Products listed may not be available in all markets.

GORE
Creative Technologies Worldwide

W. L. Gore & Associates, Inc.
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)
00800.6334.4673 (Europe)
800.437.8181 (United States)
928.779.2771 (United States)

goremedical.com